Last reviewed · How we verify
CHOP-daclizumab
CHOP-daclizumab is a Monoclonal antibody (daclizumab component) combined with chemotherapy regimen Small molecule drug developed by King's College Hospital NHS Trust. It is currently FDA-approved for T-cell lymphomas (cutaneous and systemic). Also known as: CHOP-Zenapax.
CHOP-daclizumab is a chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) combined with daclizumab, an anti-CD25 monoclonal antibody that depletes regulatory T cells to enhance immune response against lymphoid malignancies.
CHOP-daclizumab is a combination therapy that includes the drug daclizumab, which is an interleukin-2 receptor inhibitor. It is being studied as a treatment for HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL).
At a glance
| Generic name | CHOP-daclizumab |
|---|---|
| Also known as | CHOP-Zenapax |
| Sponsor | King's College Hospital NHS Trust |
| Drug class | Monoclonal antibody (daclizumab component) combined with chemotherapy regimen |
| Target | CD25 (IL-2 receptor alpha chain) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
The CHOP component is a standard cytotoxic chemotherapy regimen that directly kills rapidly dividing cancer cells. Daclizumab targets CD25 (the alpha chain of the IL-2 receptor) on regulatory T cells, reducing immunosuppression and allowing enhanced anti-tumor immunity. This combination approach aims to improve outcomes in T-cell lymphomas by combining direct cytotoxic effects with immune modulation.
Approved indications
- T-cell lymphomas (cutaneous and systemic)
Common side effects
- Myelosuppression
- Infection
- Nausea and vomiting
- Alopecia
- Immunosuppression-related complications
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CHOP-daclizumab CI brief — competitive landscape report
- CHOP-daclizumab updates RSS · CI watch RSS
- King's College Hospital NHS Trust portfolio CI
Frequently asked questions about CHOP-daclizumab
What is CHOP-daclizumab?
How does CHOP-daclizumab work?
What is CHOP-daclizumab used for?
Who makes CHOP-daclizumab?
Is CHOP-daclizumab also known as anything else?
What drug class is CHOP-daclizumab in?
What development phase is CHOP-daclizumab in?
What are the side effects of CHOP-daclizumab?
What does CHOP-daclizumab target?
Related
- Drug class: All Monoclonal antibody (daclizumab component) combined with chemotherapy regimen drugs
- Target: All drugs targeting CD25 (IL-2 receptor alpha chain)
- Manufacturer: King's College Hospital NHS Trust — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for T-cell lymphomas (cutaneous and systemic)
- Also known as: CHOP-Zenapax
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing